Pyxis Oncology, a clinical-stage company developing next-generation cancer therapeutics, has announced its participation in the BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, will participate in one-on-one meetings during the conference along with other executives.
This participation highlights Pyxis Oncology’s commitment to advancing its pipeline of therapeutics targeting hard-to-treat cancers. The company’s participation in this virtual event provides investors and industry experts with an opportunity to gain insight into Pyxis’ ongoing developments and strategic direction in the oncology space.
Pyxis Oncology launches clinical trial in new generation oncology treatment and announces participants for BTIG Virtual Biotechnology Conference, event 5-6 days in advance 2024. Lara S. Sullivan, MD, President and CEO of Pyxis, will make plans to attend the conference and will participate in the conference individually.
Pyxis Oncology Experts explore the Portalfolio il Sottolinea for monitoring the Tumor Difficili da Trattare. The presenza dell’azienda decides to hold a virtual event to obtain information on the opportunity investments and acquisition of expertise, depending on the progress of Pyxis and the Strategic Direzione Campo dell’oncologia.
Pyxis Oncology is taking on a new generation of clinical treatments and participating in the BTIG Virtual Biotechnology Conference. The event program for May 6, 2024 is as follows: Lara S. Sullivan, MD, President and CEO of Pyxis, will be joining the in-person conference call for the conference.
Participation in Pyxis Oncology is necessary to participate in advance treatment planning to overcome therapeutic difficulties. The presence of the company in this event provides an opportunity for inversors and professionals in the industry to obtain information about the data in the Pyxis process and its strategic direction in the oncology community.
Pyxis Oncology, the world’s largest biotechnology company, will host the BTIG Virtual Biotechnology Conference on August 5-6, 2024. Lara S. Sullivan, MD, MD, CEO, CEO, CEO, CEO, CEO. Join now.
It’s okay. Sorry, I’m not sure. I want to know what I’m saying.
Pyxis Oncology, working on innovative clinical development of cancer treatments, has announced its participation in the BTIG Virtual Biotechnology Conference, scheduled for the 5th and 6th of 2024. Lara S. Sullivan, MD, President and General Pyxis Management, Direction and Personal Gathering Pendant La Conference Participants.
Participation in Cette was based on Pyxis Oncology’s scientific engagement and its commitment to fair progress, the challenges of cancer treatment and evidence against the underdog. It provides information on the development strategies and directions of oncology and oncology to entrepreneurs, investors, industry experts and opportunity seekers.
Pyxis Oncology is managing the Klinischen stage, researching next-generation Krebtherapy and the BTIG Virtual Biotechnology Conference. Die Veranstaltung ist für den 5.-6. geplant in August 2024. Lara S. Sullivan, MD, President and CEO von Pyxis, serves as the head of the management of the administrative division.
Diese Teilnahme unterstreicht das Engagement von Pyxis Oncology, ihr Portfolio an Therapeutika für schwer zu behandelnde Krebserkrankungen voranzutreiben. in die laufenden Entwicklungen und die strategische Ausrichtung von Pyxis im Bereich der Onkologie zu gewinnen.
July 29, 2024 – 8:00 AM
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics targeting hard-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, and management team will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference, August 5-6, 2024.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on overcoming difficult-to-treat cancers. The company is efficiently building next-generation therapeutics with potential as monotherapy and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN in the tumor stroma, and PYX-106, a fully human Siglec-15-targeted antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical trials in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and address the underlying pathology generated by cancer that enables uncontrolled proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel strategies to target a broad range of solid tumors resistant to current standards of care. For more information, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or similar expressions or variations thereof, although not all forward-looking statements contain these words. We cannot assure you that the events or circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, the factors identified herein, the factors discussed in the “Risk Factors” section of Part II, Item 1A of the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2024, and other filings with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for the Company’s management to predict all risk factors, nor can it assess the impact that all factors may have on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in the forward-looking statements. In addition, “we believe” and similar statements reflect the Company’s beliefs and opinions with respect to the relevant subject matter. Such statements are based on information available to the Company as of the date hereof, and the Company believes such information provides a reasonable basis for such statements, but such information may be limited or incomplete, and the Company’s statements should not be construed as an indication that the Company has conducted a thorough investigation or review of all relevant information available to it. These statements are inherently uncertain, and investors are cautioned not to place undue reliance on them. Except as required by law, the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date of such statements.
Contact Pyxis Oncology
Pamela Connelly
CFO and COO
email address
FAQ
When will Pyxis Oncology (PYXS) participate in the BTIG Virtual Biotech Conference?
Pyxis Oncology (PYXS) will participate in the BTIG Virtual Biotechnology Conference on August 5-6, 2024.
Who from Pyxis Oncology (PYXS) will be attending the BTIG virtual biotech conference?
Lara S. Sullivan, M.D., president and chief executive officer of Pyxis Oncology, and other executives will attend the meeting.
What type of conference will Pyxis Oncology (PYXS) be hosting at the BTIG Virtual Biotech Conference?
Pyxis Oncology (PYXS) will participate in a one-on-one meeting during the BTIG Virtual Biotechnology Conference.
What is Pyxis Oncology’s (PYXS) research and development focus?
Pyxis Oncology (PYXS) is a clinical-stage company focused on developing next-generation therapeutics targeting hard-to-treat cancers.
